VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
SUPN
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
SUPNSupernus Pharmaceuticals, Inc.
$29.04$3.5B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksSUPNCash Flow

Supernus Pharmaceuticals, Inc. (SUPN) Cash Flow Statement

18Y historyFree accessUpdated daily

Free cash flow margin swung between -32.2% and 35.1% over the ten-quarter window, with a $293.1M net acquisition outflow in 2025Q4 indicating capital deployment has been directed primarily toward acquisitions rather than shareholder returns.

Income StatementBalance SheetCash FlowRatios

SUPN Cash Flow Statement

Annual statement

SUPN Cash Flow Statement

Supernus Pharmaceuticals, Inc. (SUPN) cash flow statement — 18-year operating, investing & financing cash flows

AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09Dec'08
Cash from Operations96M-27M36M-300M-4M353M-193M151M303M295M407M32.12M7.73M-57.95M-47.2M-36.19M-32.54M2.63M-29.65M
Operating CF Margin %--2.18%3.03%-27.45%-0.44%44.63%-29.83%19.24%31.56%25.69%42.01%22.24%6.34%-482.14%-3189.12%-4506.23%-30701.89%6.95%-333.58%
Operating CF Growth %-4038.35%-175%112%-7400%-101.13%282.9%-227.81%-50.17%2.71%-27.52%1167%315.4%113.34%-22.78%-30.44%-11.19%-1335.54%108.88%-
Net Income450M210M7M-126M-44M213M-156M178M292M193M149M14.02M19.87M-92.27M-46.28M-23.23M-39.08M4.14M-33.48M
Depreciation & Amortization13M20M28M15M16M22M26M28M16M13M14M921K928K742K871K879K1.19M1.07M1.11M
Stock-Based Compensation33M26M24M21M16M11M8M3M15M16M10M4.23M2.72M1.91M443K-82K297K111K99K
Deferred Taxes-3M-46M7M-64M00000002.15M-371K22.96M653K-16.25M-399K-4.59M0
Other Non-Cash Items37M20M16M151M-110M-66M-52M21M-49M-68M-104M748K2.09M3.03M330K2.3M-408K382.45K179K
Working Capital Changes-434M-257M-46M-297M118M173M-19M-79M29M141M338M10.06M-17.5M5.67M-3.21M188K5.85M1.52M2.44M
Change in Receivables4M3M-1M-33M-21M-25M15M79M-33M-59M-27M-8.64M-12.22M-5.04M-11K-85K284K-329K-1.16M
Change in Inventory3M18M-43M-6M-30M-3M-16M7M-31M-6M4M854K-6.29M-6M-1.15M134K294K-322K2.49M
Change in Payables000000000002.06M-1.28M8.49M-1.1M-1.1M5.21M1.81M1.09M
Cash from Investing-65M-66M69M-95M-222M-14M-4M-2M-4M-43M-35M-36.23M-4.89M-12.11M-48.96M33.9M25.82M-28.39M15.48M
Capital Expenditures-65M-66M-29M-8M-5M-4M-4M-7M-11M-30M-20M-2.1M-593K-2.35M-753K-685K-294K-714K-135K
CapEx % of Revenue4.73%5.33%2.44%0.73%0.55%0.51%0.62%0.89%1.15%2.61%2.06%1.46%0.49%19.56%50.88%85.31%277.36%1.88%1.52%
Acquisitions000-129M000000000705K00000
Investments-------------------
Other Investing-1M0-2M-42M1M-10M05M7M-13M-15M-8.51M-4.5M-705K-48.21M25.61M000
Cash from Financing-171.25M-30M-102M-64M-101M-94M-10M-13M-237M-84M-147M1.87M570K62.74M87.92M27.09M-944K4.28M64.46M
Debt Issued (Net)151.23M-17M92M-12M-3M14M-4M-4M-240M-86M-78M0065.66M-6.78M30M0075M
Equity Issued (Net)-325.46M-14M-192M-52M-98M-100M1M03M2M01.87M571K0100.73M29K4K20K0
Dividends Paid0000000000-69M00000000
Share Repurchases-302.46M-11M-173M-33M-90M-101M0000000000000
Other Financing2.98M1M-2M00-8M-7M-9M0000-1K-2.92M-6.04M-2.94M-948K4.26M-10.54M
Net Change in Cash-139M-124M3M-458M-328M244M-202M136M61M171M225M-2.24M3.42M-7.32M-8.24M24.8M-7.67M-21.47M50.29M
Free Cash Flow31M-94M5M-353M-9M319M-197M144M262M252M372M30.02M7.14M-60.3M-47.95M-36.87M-32.84M1.92M-29.79M
FCF Margin %2.26%-7.59%0.42%-32.3%-1%40.33%-30.45%18.34%27.29%21.95%38.39%20.78%5.85%-501.71%-3240%-4591.53%-30979.25%5.06%-335.1%
FCF Growth %-76.15%-1980%101.42%-3822.22%-102.82%261.93%-236.81%-45.04%3.97%-32.26%1139.22%320.43%111.84%-25.75%-30.06%-12.28%-1810.31%106.45%-
FCF per Share0.25-0.730.04-2.49-0.062.07-1.340.951.741.682.500.590.14-1.89-2.75-2.66-2.370.14-2.15
FCF Conversion (FCF/Net Income)0.07x-0.13x18.00x2.33x0.09x1.72x1.30x1.13x1.15x4.84x12.70x2.29x0.39x0.63x1.02x-0.65x0.85x5.73x0.89x
Interest Paid0000000000000000000
Taxes Paid0000000000000000000

Key Metrics

Growth RegimeMixed
ProfitabilityWeak
Balance SheetAdequate
Cash FlowMixed
Top Statement Risk

Volatile operating cash generation

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q3)

Net Income Diverges From Operating Cash

According to the supplied cash flow statements, SUPN's operating cash flow to net income ratio swung from 2.90 to -29.01 across recent quarters, indicating that reported earnings are a poor guide to actual cash generation in any single period.

The ratio's extreme dispersion suggests that quarterly net income is being driven by items such as non-cash charges, timing of revenue recognition, or non-operating gains rather than steady cash earnings. Where net income is negative but operating cash flow is positive, as in 2026Q1, working capital release or non-cash add-backs may be carrying the period, which warrants further investigation before treating either figure as representative. Investors should monitor whether conversion stabilizes over a full year rather than relying on individual quarters.

Free Cash Flow Lumpy Despite Recent Strength

Based on the reported figures, SUPN's free cash flow margin ranged from -32.2% to 35.1% over the ten-quarter window, with the most recent quarter at 23.3%, reflecting high volatility rather than a consistent upward trajectory.

The swing between deeply negative and strongly positive free cash flow suggests that the business's cash output is heavily dependent on the timing of collections and operating expense cycles. The 2026Q3 rebound to $83.0M appears encouraging, but a single strong quarter following multiple negative periods does not establish durable cash generation. Investors should monitor whether margins hold above 20% across consecutive quarters.

Working Capital Drives Quarterly Cash Variance

As reported in the cash flow statements, SUPN's working capital change moved from -$51.4M in 2025Q4 to +$21.8M in 2026Q1, a $73.2M swing that accounts for much of the period-to-period movement in operating cash flow.

The magnitude of working capital swings relative to operating cash flow suggests that receivables, inventory, or payables timing is a dominant driver of cash results rather than underlying operating performance. Large negative working capital draws in late 2025 followed by releases in early 2026 may reflect collection timing rather than structural change. Investors should monitor whether these reversals net out over a full cycle.

Acquisition Outflow Dominates Capital Use

According to the supplied filings, SUPN recorded a net acquisition outflow of $293.1M in 2025Q4 while paying no dividends and making negligible buybacks, indicating that capital deployment has been directed almost entirely toward acquisitions.

The absence of dividends and minimal repurchases suggests management has prioritized external growth over shareholder distributions during this period. The $293.1M outflow is large relative to the company's recent quarterly operating cash flow and may indicate reliance on balance sheet resources to fund growth. Investors should monitor the return on this acquisition spend against future cash flow generation.

Asset-Light Capital Intensity Persists

Based on reported figures, SUPN's capital expenditure remained below 0.6% of revenue in every quarter of the ten-quarter window, with depreciation and amortization consistently exceeding capex by a wide margin.

Capex intensity this low is characteristic of a business with limited physical asset requirements, so cash flow is less burdened by maintenance reinvestment. The persistent gap between D&A and capex suggests that the reported asset base is being amortized from prior acquisitions rather than replaced, which may flatter near-term free cash flow. Investors should monitor whether the amortization of acquired intangibles continues to depress reported earnings while leaving cash flow largely unaffected.

Quarterly Cash Strength May Be Flattering

According to the supplied cash flow data, SUPN's strong 2026Q3 free cash flow of $83.0M followed a -$5.4M quarter, so a single period of positive cash generation may overstate the durability of the recovery.

Working capital releases and non-cash add-backs such as D&A of $25.7M in 2026Q2 can lift operating cash flow in periods where underlying earnings remain weak, which may mask the operating volatility visible in the income statement. The 2026Q2 net loss of -$58.4M alongside positive D&A indicates that cash results are sensitive to accounting add-backs rather than sustained earnings power. Investors should monitor whether free cash flow remains positive once working capital effects normalize across a full year.

SUPN — Frequently Asked Questions

Quick answers to the most common questions about buying SUPN stock.

How much cash does Supernus Pharmaceuticals, Inc. (SUPN) generate from operations?

Supernus Pharmaceuticals, Inc. (SUPN) generated $-27.0M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.

What is Supernus Pharmaceuticals, Inc.'s free cash flow?

Supernus Pharmaceuticals, Inc. (SUPN) reported negative free cash flow of $94.0M in 2025, indicating capital requirements exceeded cash from operations.

What is Supernus Pharmaceuticals, Inc.'s capital expenditure (CapEx)?

Supernus Pharmaceuticals, Inc. (SUPN) spent $66.0M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.

How does Supernus Pharmaceuticals, Inc. distribute cash to shareholders?

In 2025, Supernus Pharmaceuticals, Inc. (SUPN) spent $11.0M on share repurchases. This shows the company's commitment to returning capital to its equity investors.